^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Excerpt:
Exploratory analyses suggest that PD-L2 and IFN-γ signature may be associated with clinical response to pembro and may offer additional strategies to improve prediction of response.
DOI:
10.1200/JCO.2016.34.15_suppl.6010
Trial ID: